Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015 (2015), Article ID 727650, 8 pages
http://dx.doi.org/10.1155/2015/727650
Research Article

Ginsenoside Rh1 Improves the Effect of Dexamethasone on Autoantibodies Production and Lymphoproliferation in MRL/lpr Mice

1Department of Traditional Chinese Medicine, 401 Hospital of the Chinese People’s Liberation Army, Qingdao, Shandong 266071, China
2Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
3Department of Oncology, 534 Hospital of the Chinese People’s Liberation Army, Luoyang, Henan 471003, China
4Department of Oncology, Suzhou Hospital of Traditional Chinese Medicine, Suzhou, Jiangsu 215009, China
5E-Institute of TCM Internal Medicine, Shanghai Municipal Education Commission, Shanghai 201203, China

Received 10 December 2014; Accepted 11 March 2015

Academic Editor: Fabio Firenzuoli

Copyright © 2015 Yinglu Feng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. N. Marion and A. E. Postlethwaite, “Chance, genetics, and the heterogeneity of disease and pathogenesis in systemic lupus erythematosus,” Seminars in Immunopathology, vol. 36, no. 5, pp. 495–517, 2014. View at Publisher · View at Google Scholar
  2. V. Oke and M. Wahren-Herlenius, “Cutaneous lupus erythematosus: clinical aspects and molecular pathogenesis,” Journal of Internal Medicine, vol. 273, no. 6, pp. 544–554, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. R. K. M. A. C. Luijten, R. D. Fritsch-Stork, J. W. J. Bijlsma, and R. H. W. M. Derksen, “The use of glucocorticoids in systemic lupus erythematosus. After 60 years still more an art than science,” Autoimmunity Reviews, vol. 12, no. 5, pp. 617–628, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Du, B. Cheng, X. Zhu, and C. Ling, “Ginsenoside Rg1, a novel glucocorticoid receptor agonist of plant origin, maintains glucocorticoid efficacy with reduced side effects,” The Journal of Immunology, vol. 187, no. 2, pp. 942–950, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Geiss, N. Rohleder, and F. Anton, “Evidence for an association between an enhanced reactivity of interleukin-6 levels and reduced glucocorticoid sensitivity in patients with fibromyalgia,” Psychoneuroendocrinology, vol. 37, no. 5, pp. 671–684, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. J. A. Macedo, J. Hesse, J. D. Turner, J. Meyer, D. H. Hellhammer, and C. P. Muller, “Glucocorticoid sensitivity in fibromyalgia patients: decreased expression of corticosteroid receptors and glucocorticoid-induced leucine zipper,” Psychoneuroendocrinology, vol. 33, no. 6, pp. 799–809, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. W. J. E. Tissing, J. P. P. Meijerink, M. L. den Boer, and R. Pieters, “Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia,” Leukemia, vol. 17, no. 1, pp. 17–25, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Du, M. Li, D. Zhang et al., “Flow cytometry analysis of glucocorticoid receptor expression and binding in steroid-sensitive and steroid-resistant patients with systemic lupus erythematosus,” Arthritis Research and Therapy, vol. 11, no. 4, article R108, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. J. N. Vanderbilt, R. Miesfeld, B. A. Maler, and K. R. Yamamoto, “Intracellular receptor concentration limits glucocorticoid-dependent enhancer activity,” Molecular Endocrinology, vol. 1, no. 1, pp. 68–74, 1987. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Binbin, F. Yinglu, D. Juan, and L. Changquan, “Upregulation effect of ginsenosides on glucocorticoid receptor in rat liver,” Hormone and Metabolic Research, vol. 41, no. 7, pp. 531–536, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Li, C.-Q. Ling, X.-Q. Huang, and Z.-L. Shen, “Effects of ginsenosides extracted from ginseng stem and leaves on glucocorticoid receptor in different viscera in heat-damaged rats,” Zhong Xi Yi Jie He Xue Bao, vol. 4, no. 2, pp. 156–159, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Ling, Y. Li, X. Zhu, C. Zhang, and M. Li, “Ginsenosides may reverse the dexamethasone-induced down-regulation of glucocorticoid receptor,” General and Comparative Endocrinology, vol. 140, no. 3, pp. 203–209, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Li, J. Du, D. Liu et al., “Ginsenoside Rh1 potentiates dexamethasone's anti-inflammatory effects for chronic inflammatory disease by reversing dexamethasone-induced resistance,” Arthritis Research and Therapy, vol. 16, no. 3, article R106, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. S. E. Wenderfer, B. Ke, T. J. Hollmann, R. A. Wetsel, H. Y. Lan, and M. C. Braun, “C5a receptor deficiency attenuates T cell function and renal disease in MRLIpr mice,” Journal of the American Society of Nephrology, vol. 16, no. 12, pp. 3572–3582, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. F. A. Kabeer, G. B. Sreedevi, M. S. Nair et al., “Antineoplastic effects of deoxyelephantopin, a sesquiterpene lactone from Elephantopus scaber, on lung adenocarcinoma (A549) cells,” Journal of Chinese Integrative Medicine, vol. 11, no. 4, pp. 269–277, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Li, X. Wang, S. Cheng et al., “Diosgenin induces G2/M cell cycle arrest and apoptosis in human hepatocellular carcinoma cells,” Oncology Reports, vol. 33, no. 2, pp. 693–698, 2014. View at Publisher · View at Google Scholar
  17. B. Cheng, J. Li, J. Du, X. Lv, L. Weng, and C. Ling, “Ginsenoside Rb1 inhibits osteoclastogenesis by modulating NF-κB and MAPKs pathways,” Food and Chemical Toxicology, vol. 50, no. 5, pp. 1610–1615, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. X. Zhang, J. Zhu, W. Geng et al., “Electroacupuncture at Feishu (BL13) and Zusanli (ST36) down-regulates the expression of orexins and their receptors in rats with chronic obstructive pulmonary disease,” Journal of Integrative Medicine, vol. 12, no. 5, pp. 417–424, 2014. View at Publisher · View at Google Scholar
  19. T. J. Santoro, J. P. Portanova, and B. L. Kotzin, “The contribution of L3T4+ T cells to lymphoproliferation and autoantibody production in MRL-lpr/lpr mice,” Journal of Experimental Medicine, vol. 167, no. 5, pp. 1713–1718, 1988. View at Publisher · View at Google Scholar · View at Scopus
  20. F. X. O'Sullivan, C. J. Ray, Y. Takeda, G. C. Sharp, and S. E. Walker, “Long-term anti-CD4 treatment of MRL/lpr mice ameliorates immunopathology and lymphoproliferation but fails to suppress rheumatoid factor production,” Clinical Immunology and Immunopathology, vol. 61, no. 3, pp. 421–435, 1991. View at Publisher · View at Google Scholar · View at Scopus
  21. D. A. Jabs, C. L. Burek, Q. Hu, R. C. Kuppers, B. Lee, and R. A. Prendergast, “Anti-CD4 monoclonal antibody therapy suppresses autoimmune disease in MRL/Mp-lpr/lpr mice,” Cellular Immunology, vol. 141, no. 2, pp. 496–507, 1992. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Okazaki, D. Hirata, T. Kamimura et al., “Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus,” Journal of Rheumatology, vol. 29, no. 4, pp. 707–716, 2002. View at Google Scholar · View at Scopus
  23. Y. Shi, S. Devadas, K. M. Greeneltch, D. Yin, R. A. Mufson, and J.-N. Zhou, “Stressed to death: Implication of lymphocyte apoptosis for psychoneuroimmunology,” Brain, Behavior, and Immunity, vol. 17, supplement 1, pp. S18–S26, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. J. D. Amaral, S. Solá, C. J. Steer, and C. M. P. Rodrigues, “Role of nuclear steroid receptors in apoptosis,” Current Medicinal Chemistry, vol. 16, no. 29, pp. 3886–3902, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Dörner, C. Giesecke, and P. E. Lipsky, “Mechanisms of B cell autoimmunity in SLE,” Arthritis Research & Therapy, vol. 13, no. 5, article 243, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Hanaoka, Y. Okazaki, T. Satoh et al., “Circulating anti-double-stranded DNA antibody-secreting cells in patients with systemic lupus erythematosus: a novel biomarker for disease activity,” Lupus, vol. 21, no. 12, pp. 1284–1293, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Villalta, N. Bizzaro, N. Bassi et al., “Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease,” PLoS ONE, vol. 8, no. 8, Article ID e71458, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Q. Qu, W. H. Bian, and Y. Y. Xu, “A novel NF-κB inhibitor, DHMEQ, ameliorates pristane-induced lupus in mice,” Experimental and Therapeutic Medicine, vol. 8, no. 1, pp. 100–104, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. C. P. Nguyen, V. V. Cao, J. Fehér, and P. Gergely, “Correlation between the levels of antinuclear antibodies, anti-DNA antibodies, and complement in systemic lupus erythematosus.,” Acta Medica Hungarica, vol. 45, no. 2, pp. 145–159, 1988. View at Google Scholar · View at Scopus
  30. E. Paz, M. Adawi, I. Lavi, Y. Mussel, and R. Mader, “Antinuclear antibodies measured by enzyme immunoassay in patients with systemic lupus erythematosus: relation to disease activity,” Rheumatology International, vol. 27, no. 10, pp. 941–945, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Almogren, “Anti-double stranded antibody: association with titers and fluorescence patterns of anti-nuclear antibody in systemic lupus erythematosus,” Saudi Medical Journal, vol. 31, no. 1, pp. 32–36, 2010. View at Google Scholar · View at Scopus
  32. M. Herrmann, O. M. Zoller, M. Hagenhofer, R. Voll, and J. R. Kalden, “What triggers anti-dsDNA antibodies?” Molecular Biology Reports, vol. 23, no. 3-4, pp. 265–267, 1996. View at Publisher · View at Google Scholar · View at Scopus
  33. D.-R. Koh, A. Ho, A. Rahemtulla, W.-P. Fung-Leung, H. Griesser, and T.-W. Mak, “Murine lupus in MRL/lpr mice lacking CD4 or CD8 T cells,” European Journal of Immunology, vol. 25, no. 9, pp. 2558–2562, 1995. View at Publisher · View at Google Scholar · View at Scopus
  34. D. A. Jabs, B. Lee, and R. A. Prendergast, “Role of T cells in the pathogenesis of autoimmune lacrimal gland disease in MRL/Mp-lpr/lpr mice,” Current Eye Research, vol. 16, no. 9, pp. 909–916, 1997. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Rönnblom and G. V. Alm, “A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus,” Journal of Experimental Medicine, vol. 194, no. 12, pp. F59–F63, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. B. M. Rüger, K. J. Erb, Y. He, J. M. Lane, P. F. Davis, and Q. Hasan, “Interleukin-4 transgenic mice develop glomerulosclerosis independent of immunoglobulin deposition,” European Journal of Immunology, vol. 30, no. 9, pp. 2698–2703, 2000. View at Google Scholar
  37. A. Csiszár, G. Nagy, P. Gergely, T. Pozsonyi, and É. Pócsik, “Increased interferon-gamma (IFN-γ), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE),” Clinical and Experimental Immunology, vol. 122, no. 3, pp. 464–470, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Sugimoto, S. Morimoto, H. Kaneko et al., “Decreased IL-4 producing CD4+ T cells in patients with active systemic lupus erythematosus-relation to IL-12R expression,” Autoimmunity, vol. 35, no. 6, pp. 381–387, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Y. Wu, C. Fargeas, T. Nakajima, and G. Delespesse, “Glucocorticoids suppress the production of interleukin 4 by human lymphocytes,” European Journal of Immunology, vol. 21, no. 10, pp. 2645–2647, 1991. View at Publisher · View at Google Scholar · View at Scopus
  40. R. A. Daynes and B. A. Araneo, “Contrasting effects of glucocorticoids on the capacity of T cells to produce the growth factors interleukin 2 and interleukin 4,” European Journal of Immunology, vol. 19, no. 12, pp. 2319–2325, 1989. View at Publisher · View at Google Scholar · View at Scopus
  41. H.-F. Xie, J. Li, and W. Shi, “Effect of corticosteroids on the balance of Th cytokines in patients with systemic lupus erythematosus,” Hunan Yi Ke Da Xue Xue Bao, vol. 27, no. 6, pp. 533–535, 2002. View at Google Scholar · View at Scopus
  42. D. K. L. Choy, F. Ko, S. T. Li et al., “Effects of theophylline, dexamethasone and salbutamol on cytokine gene expression in human peripheral blood CD4+ T-cells,” European Respiratory Journal, vol. 14, no. 5, pp. 1106–1112, 1999. View at Publisher · View at Google Scholar · View at Scopus
  43. F. Ramírez, “Glucocorticoids induce a Th2 response in vitro,” Developmental Immunology, vol. 6, no. 3-4, pp. 233–243, 1998. View at Publisher · View at Google Scholar · View at Scopus
  44. S. K. Agarwal and D. Marshall Jr., “Dexamethasone promotes type 2 cytokine production primarily through inhibition of type 1 cytokines,” Journal of Interferon and Cytokine Research, vol. 21, no. 3, pp. 147–155, 2001. View at Publisher · View at Google Scholar · View at Scopus